Show simple item record

dc.contributor.authorDiehl, Volker
dc.contributor.authorSextro, Michael
dc.contributor.authorFranklin, Jeremy
dc.contributor.authorHansmann, Martin-Leo
dc.contributor.authorHarris, Nancy
dc.contributor.authorJaffe, Elaine
dc.contributor.authorPoppema, Sibrand
dc.contributor.authorHarris, Martin
dc.contributor.authorFranssila, Kaarle
dc.contributor.authorVan Krieken, Jan
dc.contributor.authorMarafioti, Theresa
dc.contributor.authorAnagnostopoulos, Ioannis
dc.contributor.authorStein, Harald
dc.date.accessioned2009-12-14T15:26:40Z
dc.date.available2009-12-14T15:26:40Z
dc.date.issued1999-03
dc.identifier.citationClinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. 1999, 17 (3):776-83 J. Clin. Oncol.en
dc.identifier.issn0732-183X
dc.identifier.pmid10071266
dc.identifier.urihttp://hdl.handle.net/10541/87901
dc.description.abstractPURPOSE: Recent studies have suggested that lymphocyte-predominant Hodgkin's disease (LPHD) is both clinically and pathologically distinct from other forms of Hodgkin's disease, including classical Hodgkin's disease (CHD). However, large-scale clinical studies were lacking. This multicenter, retrospective study investigated the clinical characteristics and course of LPHD patients and lymphocyte-rich classical Hodgkin's disease (LRCHD) patients classified according to morphologic and immunophenotypic criteria. MATERIALS AND METHODS: Clinical data and biopsy material of all available cases initially submitted as LPHD were collected from 17 European and American centers, stained, and reclassified by expert pathologists. RESULTS: The 426 assessable cases were reclassified as LPHD (51%), LRCHD (27%), CHD (5%), non-Hodgkin's lymphoma (3%), and reactive lesion (3%); 11% of cases were not assessable. Patients with LPHD and LRCHD were predominantly male, with early-stage disease and few risk factors. Patients with LRCHD were significantly older. Survival and failure-free survival rates with adequate therapy were similar for patients with LPHD and LRCHD, and were stage-dependent and not significantly better than stage-comparable results for CHD (German trial data). Twenty-seven percent of relapsing LPHD patients had multiple relapses, which is significantly more than the 5% of relapsing LRCHD patients who had multiple relapses. Lymphocyte-predominant Hodgkin's disease patients had significantly superior survival after relapse compared with LRCHD or CHD patients; however, this was partly due to the younger average age of LPHD patients. CONCLUSION: The two subgroups of LPHD and LRCHD bore a close clinical resemblance that was distinct from CHD; the course was similar to that of comparable nodular sclerosis and mixed cellularity patients. Thorough staging is necessary to detect advanced disease in LPHD and LRCHD patients. The question of how to treat such patients, either by reducing treatment intensity or following a "watch and wait" approach, remains unanswered.
dc.language.isoenen
dc.subjectCancer Stagingen
dc.subjectSecond Primary Canceren
dc.subject.meshAdult
dc.subject.meshAge Factors
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCause of Death
dc.subject.meshCohort Studies
dc.subject.meshCombined Modality Therapy
dc.subject.meshDisease-Free Survival
dc.subject.meshFemale
dc.subject.meshHodgkin Disease
dc.subject.meshHumans
dc.subject.meshLymphocytes
dc.subject.meshLymphoma, Non-Hodgkin
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Staging
dc.subject.meshNeoplasms, Second Primary
dc.subject.meshPrognosis
dc.subject.meshRemission Induction
dc.subject.meshSex Factors
dc.titleClinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.en
dc.typeArticleen
dc.contributor.departmentDepartment of Internal Medicine, University of Cologne, Germany.en
dc.identifier.journalJournal of Clinical Oncologyen
html.description.abstractPURPOSE: Recent studies have suggested that lymphocyte-predominant Hodgkin's disease (LPHD) is both clinically and pathologically distinct from other forms of Hodgkin's disease, including classical Hodgkin's disease (CHD). However, large-scale clinical studies were lacking. This multicenter, retrospective study investigated the clinical characteristics and course of LPHD patients and lymphocyte-rich classical Hodgkin's disease (LRCHD) patients classified according to morphologic and immunophenotypic criteria. MATERIALS AND METHODS: Clinical data and biopsy material of all available cases initially submitted as LPHD were collected from 17 European and American centers, stained, and reclassified by expert pathologists. RESULTS: The 426 assessable cases were reclassified as LPHD (51%), LRCHD (27%), CHD (5%), non-Hodgkin's lymphoma (3%), and reactive lesion (3%); 11% of cases were not assessable. Patients with LPHD and LRCHD were predominantly male, with early-stage disease and few risk factors. Patients with LRCHD were significantly older. Survival and failure-free survival rates with adequate therapy were similar for patients with LPHD and LRCHD, and were stage-dependent and not significantly better than stage-comparable results for CHD (German trial data). Twenty-seven percent of relapsing LPHD patients had multiple relapses, which is significantly more than the 5% of relapsing LRCHD patients who had multiple relapses. Lymphocyte-predominant Hodgkin's disease patients had significantly superior survival after relapse compared with LRCHD or CHD patients; however, this was partly due to the younger average age of LPHD patients. CONCLUSION: The two subgroups of LPHD and LRCHD bore a close clinical resemblance that was distinct from CHD; the course was similar to that of comparable nodular sclerosis and mixed cellularity patients. Thorough staging is necessary to detect advanced disease in LPHD and LRCHD patients. The question of how to treat such patients, either by reducing treatment intensity or following a "watch and wait" approach, remains unanswered.


This item appears in the following Collection(s)

Show simple item record